Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Tveteraas, Ingun Heiene ^a   Müller, Kristin Meisdalen ^a   Aasrum, Monica ^a   Ødegård, John ^a   Dajani, Olav ^b   Guren, Tormod ^b   Sandnes, Dagny ^a   Christoffersen, Thoralf ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

EGF receptor; Hepatocarcinoma cells; Hepatocytes; Prostaglandin receptors; Transactivation

Indexed keywords

CALCIUM; DNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; INOSITOL PHOSPHATE; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROTEIN KINASE B; PROTEIN KINASE P60; THYMIDINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CANCER CELL CULTURE; CARCINOMA CELL; CELL STIMULATION; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVATION; LIVER CELL; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RADIOIMMUNOASSAY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER TUMOR; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DINOPROSTONE; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84865959205     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-72     Document Type: Article

References (63)

1. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Daub H, Weiss FU, Wallasch C, Ullrich A, Nature 1996 379 6565 557 560 10.1038/379557a0 8596637 (Pubitemid 26049585)
2. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A, Nature 1999 402 6764 884 888 10622253
3. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. Buchanan FG, Wang D, Bargiacchi F, DuBois RN, J Biol Chem 2003 278 37 35451 35457 10.1074/jbc.M302474200 12824187 (Pubitemid 37102315)
4. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. Schafer B, Marg B, Gschwind A, Ullrich A, J Biol Chem 2004 279 46 47929 47938 10.1074/jbc.M400129200 15337756 (Pubitemid 39540944)
5. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Bhola NE, Grandis JR, Front Biosci 2008 13 1857 1865 10.2741/2805 17981673 (Pubitemid 351599738)
6. Epidermal growth factor. Carpenter G, Cohen S, J Biol Chem 1990 265 14 7709 7712 2186024 (Pubitemid 20158927)
7. Epidermal growth factor receptor: mechanisms of activation and signalling. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW, Exp Cell Res 2003 284 1 31 53 10.1016/S0014-4827(02)00098-8 12648464 (Pubitemid 36331965)
8. The ErbB receptors and their role in cancer progression. Holbro T, Civenni G, Hynes NE, Exp Cell Res 2003 284 1 99 110 10.1016/S0014-4827(02)00099- X 12648469 (Pubitemid 36331969)
9. Epidermal growth factor receptor (EGFR) signaling in cancer. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS, Gene 2006 366 1 2 16 10.1016/j.gene.2005.10.018 16377102 (Pubitemid 43199589)
10. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. Christoffersen T, Guren TK, Spindler KL, Dahl O, Lonning PE, Gjertsen BT, Eur J Pharmacol 2009 625 1-3 6 22 19836383
11. EGFR antagonists in cancer treatment. Ciardiello F, Tortora G, N Engl J Med 2008 358 11 1160 1174 10.1056/NEJMra0707704 18337605 (Pubitemid 351398490)
12. Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. Müller KM, Tveteraas IH, Aasrum M, Odegard J, Dawood M, Dajani O, Christoffersen T, Sandnes DL, BMC Cancer 2011 11 421 10.1186/1471-2407-11-421 21961726
13. Temporal requirement for epidermal growth factor and insulin in the stimulation of hepatocyte DNA synthesis. Sand TE, Christoffersen T, J Cell Physiol 1987 131 2 141 148 10.1002/jcp.1041310202 3294862 (Pubitemid 17106588)
14. Transforming growth factor alpha may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Mead JE, Fausto N, Proc Natl Acad Sci U S A 1989 86 5 1558 1562 10.1073/pnas.86.5.1558 2922399 (Pubitemid 19078942)
15. Mechanisms of hepatocyte growth regulation by hormones and growth factor. Christoffersen T, Thoresen GH, Dajani OF, Melien Ø Guren T, Refsnes M, Sandnes D, The hepatocyte review. edn. Edited by AM BMaE Kluwer Academic Publishers, Dordrecht/Boston/London 2000 209 246
16. Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation. Scheving LA, Stevenson MC, Taylormoore JM, Traxler P, Russell WE, Biochem Biophys Res Commun 2002 290 1 197 203 10.1006/bbrc.2001.6157 11779153 (Pubitemid 34694483)
17. Hepatocellular carcinoma pathogenesis: from genes to environment. Farazi PA, DePinho RA, Nat Rev Cancer 2006 6 9 674 687 10.1038/nrc1934 16929323 (Pubitemid 44286000)
18. Genomics and signaling pathways in hepatocellular carcinoma. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM, Semin Liver Dis 2007 27 1 55 76 10.1055/s-2006-960171 17295177
19. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Whittaker S, Marais R, Zhu AX, Oncogene 2010 29 36 4989 5005 10.1038/onc.2010.236 20639898
20. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Berasain C, Castillo J, Prieto J, Avila MA, Liver Int 2007 27 2 174 185 10.1111/j.1478-3231.2006.01424.x 17311611 (Pubitemid 46680720)
21. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT, Cell 1990 61 6 1137 1146 10.1016/0092-8674(90)90076-Q 2350785 (Pubitemid 20203495)
22. Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver. Sandgren EP, Luetteke NC, Qiu TH, Palmiter RD, Brinster RL, Lee DC, Mol Cell Biol 1993 13 1 320 330 8417334 (Pubitemid 23006909)
23. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, Miyoshi E, Monden M, Matsuura N, Br J Cancer 2001 84 10 1377 1383 10.1054/bjoc.2000.1580 11355950 (Pubitemid 32522107)
24. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. Hopfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherubl H, J Hepatol 2004 41 6 1008 1016 10.1016/j.jhep.2004.08.024 15582135 (Pubitemid 39575669)
25. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H, Biochem Pharmacol 2005 70 11 1568 1578 10.1016/j.bcp.2005.09.007 16226226 (Pubitemid 41540350)
26. Targeted therapies for hepatocellular carcinoma. Villanueva A, Llovet JM, Gastroenterology 2011 140 5 1410 1426 10.1053/j.gastro.2011.03.006 21406195
27. Prostanoid receptors: subtypes and signaling. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD, Annu Rev Pharmacol Toxicol 2001 41 661 690 10.1146/annurev.pharmtox.41.1.661 11264472 (Pubitemid 32385902)
28. Eicosanoids and cancer. Wang D, Dubois RN, Nat Rev Cancer 2010 10 3 181 193 10.1038/nrc2809 20168319
29. Cyclooxygenase in biology and disease. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE, FASEB J 1998 12 12 1063 1073 9737710 (Pubitemid 28418937)
30. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Gupta RA, Dubois RN, Nat Rev Cancer 2001 1 1 11 21 10.1038/35094017 11900248 (Pubitemid 33741877)
31. Cyclooxygenases in cancer: progress and perspective. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM, Cancer Lett 2004 215 1 1 20 10.1016/j.canlet.2004.06.014 15374627 (Pubitemid 39221453)
32. Stimulation of DNA synthesis and mitosis of hepatocytes in primary cultures of neonatal rat liver by arachidonic acid and prostaglandins. Andreis PG, Whitfield JF, Armato U, Exp Cell Res 1981 134 2 265 272 10.1016/0014- 4827(81)90425-0 6791948 (Pubitemid 12243901)
33. On the mechanisms of the growth-promoting effect of prostaglandins in hepatocytes: the relationship between stimulation of DNA synthesis and signaling mediated by adenylyl cyclase and phosphoinositide-specific phospholipase C. Refsnes M, Dajani OF, Sandnes D, Thoresen GH, Rottingen JA, Iversen JG, Christoffersen T, J Cell Physiol 1995 164 3 465 473 10.1002/jcp.1041640304 7650056
34. Stimulation of hepatocyte DNA synthesis by prostaglandin E2 and prostaglandin F2 alpha: additivity with the effect of norepinephrine, and synergism with epidermal growth factor. Refsnes M, Thoresen GH, Dajani OF, Christoffersen T, J Cell Physiol 1994 159 1 35 40 10.1002/jcp.1041590106 8138589 (Pubitemid 24234574)
35. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, et al. Hepatology 1999 29 3 688 696 10.1002/hep.510290355 10051469 (Pubitemid 29109581)
36. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. Tang TC, Poon RT, Lau CP, Xie D, Fan ST, World J Gastroenterol 2005 11 13 1896 1902 15800977 (Pubitemid 40520983)
37. Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes. Dajani OF, Meisdalen K, Guren TK, Aasrum M, Tveteraas IH, Lilleby P, Thoresen GH, Sandnes D, Christoffersen T, J Cell Physiol 2008 214 2 371 380 10.1002/jcp.21205 17654493 (Pubitemid 350308993)
38. G protein-coupled receptor agonist-stimulated expression of ATF3/LRF-1 and c-myc and comitogenic effects in hepatocytes do not require EGF receptor transactivation. Nilssen LS, Odegard J, Thoresen GH, Molven A, Sandnes D, Christoffersen T, J Cell Physiol 2004 201 3 349 358 10.1002/jcp.20075 15389557 (Pubitemid 39453120)
39. Establishment of a clonal strain of hepatoma cells which secrete albumin. Richardson UI, Tashjian AH Jr, Levine L, J Cell Biol 1969 40 1 236 247 10.1083/jcb.40.1.236 4177659
40. Changes in hormone responsiveness and cyclic AMP metabolism in rat hepatocytes during primary culture and effects of supplementing the medium with insulin and dexamethasone. Christoffersen T, Refsnes M, Bronstad GO, Ostby E, Huse J, Haffner F, Sand TE, Hunt NH, Sonne O, Eur J Biochem 1984 138 2 217 226 10.1111/j.1432-1033.1984.tb07904.x 6321168 (Pubitemid 14180944)
41. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. Bustin SA, J Mol Endocrinol 2000 25 2 169 193 10.1677/jme.0.0250169 11013345
42. A radioimmunoassay for cyclic AMP (cAMP) obtained by acetylation of both unlabeled and labeled (3 H-cAMP) ligand, or of unlabeled ligand only. Skomedal T, Grynne B, Osnes JB, Sjetnan AE, Oye I, Acta Pharmacol Toxicol (Copenh) 1980 46 3 200 204 (Pubitemid 10176764)
43. Prostaglandin E receptors. Sugimoto Y, Narumiya S, J Biol Chem 2007 282 16 11613 11617 17329241 (Pubitemid 47100657)
44. EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway. Ji R, Chou CL, Xu W, Chen XB, Woodward DF, Regan JW, Mol Pharmacol 2010 77 6 1025 1036 10.1124/mol.110.063933 20335389
45. AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. Griffin BW, Klimko P, Crider JY, Sharif NA, J Pharmacol Exp Ther 1999 290 3 1278 1284 10454504 (Pubitemid 29400270)
46. Prostaglandin receptor EP(4) mediates the bone anabolic effects of PGE(2). Machwate M, Harada S, Leu CT, Seedor G, Labelle M, Gallant M, Hutchins S, Lachance N, Sawyer N, Slipetz D, et al. Mol Pharmacol 2001 60 1 36 41 11408598 (Pubitemid 32595231)
47. Protein kinase Calpha mediates feedback inhibition of EGF receptor transactivation induced by Gq-coupled receptor agonists. Santiskulvong C, Rozengurt E, Cell Signal 2007 19 6 1348 1357 10.1016/j.cellsig.2007.01.006 17307332 (Pubitemid 46578337)
48. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP, Proc Natl Acad Sci U S A 1990 87 7 2466 2470 10.1073/pnas.87.7.2466 2138778
49. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Ohtsu H, Dempsey PJ, Eguchi S, Am J Physiol Cell Physiol 2006 291 1 1 C10 10.1152/ajpcell.00620.2005 16769815
50. Galardin (GM 6001), a broad-spectrum matrix metalloproteinase inhibitor, blocks bombesin- and LPA-induced EGF receptor transactivation and DNA synthesis in rat-1 cells. Santiskulvong C, Rozengurt E, Exp Cell Res 2003 290 2 437 446 10.1016/S0014-4827(03)00355-0 14568001 (Pubitemid 37272186)
51. Role of ErbB2 in the prostaglandin E(2)-induced enhancement of the mitogenic response to epidermal growth factor in cultured hepatocytes. Odegard J, Aasrum M, Tveteraas IH, Bharath SP, Sandnes D, Christoffersen T, Biochem Biophys Res Commun 2012 421 2 255 260 10.1016/j.bbrc.2012.03.148 22503980
52. Prostaglandins enhance epidermal growth factor-induced DNA synthesis in hepatocytes by stimulation of E prostanoid 3 and F prostanoid receptors. Meisdalen K, Dajani OF, Christoffersen T, Sandnes D, J Pharmacol Exp Ther 2007 322 3 1044 1050 10.1124/jpet.107.121277 17567965 (Pubitemid 47295800)
53. The regulation of cyclic AMP levels in cultured MH1C1 rat hepatoma cells and in solid tumours derived from MH1C1 cell inoculates. Bronstad GO, Gladhaug IP, Haffner F, Rugstad HE, Christoffersen T, Anticancer Res 1987 7 2 155 160 3035996 (Pubitemid 17117939)
54. Prostaglandins induce proliferation of rat hepatocytes through a prostaglandin E2 receptor EP3 subtype. Hashimoto N, Watanabe T, Ikeda Y, Yamada H, Taniguchi S, Mitsui H, Kurokawa K, Am J Physiol 1997 272 3 Pt 1 597 G604 9124580
55. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, Sugimoto Y, Negishi M, Narumiya S, Sugimura T, et al. Gut 2004 53 8 1151 1158 10.1136/gut.2003.028787 15247185 (Pubitemid 38961971)
56. Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade. Andreev J, Galisteo ML, Kranenburg O, Logan SK, Chiu ES, Okigaki M, Cary LA, Moolenaar WH, Schlessinger J, J Biol Chem 2001 276 23 20130 20135 10.1074/jbc.M102307200 11274221
57. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. Han C, Michalopoulos GK, Wu T, J Cell Physiol 2006 207 1 261 270 10.1002/jcp.20560 16331686
58. Angiotensin II and epidermal growth factor receptor cross-talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. Itabashi H, Maesawa C, Oikawa H, Kotani K, Sakurai E, Kato K, Komatsu H, Nitta H, Kawamura H, Wakabayashi G, et al. Hepatol Res 2008 38 6 601 613 10.1111/j.1872-034X.2007.00304.x 18452483 (Pubitemid 351622286)
59. Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis. Caja L, Ortiz C, Bertran E, Murillo MM, Miro-Obradors MJ, Palacios E, Fabregat I, Cell Signal 2007 19 4 683 694 10.1016/j.cellsig.2006.09.002 17055226 (Pubitemid 46275361)
60. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS, Nat Med 2002 8 3 289 293 10.1038/nm0302-289 11875501 (Pubitemid 34250108)
61. Signal characteristics of G protein-transactivated EGF receptor. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A, EMBO J 1997 16 23 7032 7044 10.1093/emboj/16.23.7032 9384582 (Pubitemid 27520803)
62. EGFR signal transactivation in cancer cells. Fischer OM, Hart S, Gschwind A, Ullrich A, Biochem Soc Trans 2003 31 Pt 6 1203 1208 14641026 (Pubitemid 38030939)
63. Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. Kisfalvi K, Guha S, Rozengurt E, J Cell Physiol 2005 202 3 880 890 10.1002/jcp.20187 15389644 (Pubitemid 40175866)